Cancer Medicine MD

University of Liverpool

Undertake research that offers the opportunity to make significant impact on the detection and treatment of cancer with our Cancer Medicine programme. You’ll explore laboratory-based or clinical trial-based approaches to the study of cancer and examine therapeutic strategies that impact upon medicine and ultimately improve patient outcomes.IntroductionThe Institute of Systems, Molecular and Integrative Biology (ISMIB) was established to integrate cutting-edge and clinical research across the Faculty of Health and Life Sciences. Programmes of work across ISMIB are varied and are led by world experts in their fields.A broad range of research interests provides for world-class research in cancer medicine, supported by world-class clinical research into several major types of cancer. Cancer medicine research is aimed at developing discoveries that can ultimately be translated into patient benefits. You will undertake fundamental research into the mechanisms leading to cancer development and progression, with the aim of understanding the processes that lead to cancer development, and which constitute potential therapeutic targets. This is achieved by translational research, taking advantage of new and on-going clinical trials in cancer. These combine existing therapies with novel approaches, using predictive and prognostic biomarkers.Scientific research is performed in an environment with a wealth of clinical expertise and research. This ensures that scientific research is always provided by leading clinical teams, informed by an awareness of detailed clinical issues, and performed with insights of relevance to patients.Research topicsWe offer translational research and tumour-specific research in many areas including:Pancreatic cancerColorectal cancerHaemato-oncologyHead and neck cancerLiver cancerLung cancerGastro-oesophageal cancerBrain cancerBreast cancer.Research themes include:Early detection, screening and diagnosis of cancersCancer vulnerabilities, novel therapeutics and therapy response markersTumour-stroma-immune interactionsCell-signalling, membrane to nucleus.

University of Liverpool